Revenue segments as reported by the company.

Companion Animal

Livestock

Contract Manufacturing & Human Health

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Interest expense

Other (income)/deductions–net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zoetis

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision livestock farming technology. The firm operates through the following segments: United States & International. Its products include vaccines, parasiticides, anti-infectives, dermatology products, medicated feed additives, animal health diagnostics, and other pharmaceutical products for both companion animal and livestock customers. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zoetis reports robust 2022 results, eyes growth in key markets

Zoetis delivered strong financial performance in 2022 and projects continued growth in 2023. The company's investments in R&D, CapEx, and customer engagement strategies position it well for future competition. Challenges from inflation, competition, and supply chain issues require careful navigation, but opportunities in key growth areas offer potential for sustained success.

Zoetis reports solid Q1 results, reaffirms full-year guidance

Zoetis delivered solid Q1 results despite challenges in certain segments. The company remains optimistic about future growth opportunities, supported by upcoming product launches and strategic investments. Investor Day will provide detailed insights into Zoetis' growth strategy and innovation pipeline.

Zoetis reports robust Q2 earnings, eyes global market expansion

Zoetis delivered strong financial results in Q2 2023, with expectations of continued growth in operational revenue and adjusted net income for the full year. The company remains focused on driving revenue growth through industry tailwinds and innovation over the next few years.

Zoetis reports robust Q3 performance and anticipates accelerated growth

Zoetis' Q3 2023 performance reflects strong revenue and income growth, supported by successful product launches and a robust diagnostics portfolio.
While facing challenges from upcoming competition and margin pressures, the company remains confident in its growth prospects for 2023 and 2024.
Opportunities lie in accelerated growth driven by key products, macro trends in animal health, and ongoing investments in innovation and cost management.
Overall, Zoetis' strategic strengths position it well to navigate challenges and capitalize on opportunities for sustained growth and value creation.

Zoetis reports robust 2023 results and sets sights on international growth

Zoetis delivered strong financial performance in 2023, driven by innovative products and operational growth across portfolios. The company is well-positioned for continued growth in 2024, focusing on innovation, market leadership, and addressing challenges like currency dynamics and capacity constraints. Opportunities lie in international markets, DTC initiatives, and sustained revenue growth.

Zoetis excels in Q1 with double-digit growth and strategic focus

Zoetis' Q1 performance reflects strong revenue and income growth, driven by successful product launches and market leadership. The company's focus on innovation, quality, and strategic divestments positions it well for future growth. Challenges in livestock and competition require strategic adaptation, while opportunities in product growth and market expansion offer promising avenues for development.

Zoetis excels in Q2 2024, raises guidance and announces buyback

Zoetis' Q2 2024 performance highlights its strong market position, driven by innovative products and strategic initiatives. While challenges exist in the competitive landscape, the company's focus on customer-centric innovation and financial strength position it well for future growth. With raised guidance and shareholder value initiatives, Zoetis is poised for continued success in the animal health industry.

Zoetis reports strong Q3 earnings and eyes sustained growth

Zoetis delivered robust operational growth in Q3 2024, driven by strong performance in key segments and products, leading to a revised full year guidance and confidence in future prospects.
Despite potential challenges in navigating a dynamic landscape and supply chain efficiency, Zoetis remains well-positioned to capitalize on opportunities for growth in 2025 through innovation and market expansion.
With a focus on sustained above-industry average growth, Zoetis' strategic strengths in key franchises and market positioning reinforce their leadership in the animal health industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Zoetis' (ZTS) revenues are expected to boost the pet care and livestock product sales in the quarters ahead. Disease outbreaks and potential supply challenges hurt prospects.

Zoetis' (ZTS) Companion Animal Products to Boost Revenues

DURHAM, N.C.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis, the world's leading animal health company, is pleased to invite members of the media to attend a ribbon-cutting event to mark the official opening of a new building dedicated to diagnostics and biodevices research and development (R&D) to meet the needs of veterinarians, livestock farmers and pet owners. The expanded site will serve as the hub for Zoetis' engineering and diagnostics work including device reliability testing. The new building features m.

Media Advisory: Ribbon-cutting Ceremony for new Zoetis facility in Durham, N.C., to expand diagnostics R&D and engineering capabilities and bring more jobs to Durham

Automatic Data Processing

Cigna

Coterra Energy

Deere & Company

Dick's Sporting Goods

Intuit

Mastercard

Old Dominion Freight Line

PulteGroup

Vanguard Dividend Appreciation ETF

This monthly series of articles focuses on DGI stocks that are likely to provide a high rate of dividend growth rather than a high current yield. We use our proprietary models to rate quantitatively and qualitatively and select the top ten names from an initial list of nearly 400 dividend stocks. The article provides criteria for selecting high-growth dividend stocks and offers a step-by-step guide on how to structure a portfolio based on this strategy.

Our Top 10 Picks For Dividend Growth Stocks - August 2023

IQVIA Hlds

Eli Lilly

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

West Pharmaceutical Services

For investors, tracking the stocks that are up in what has otherwise been a grim year for drugmakers can help identify trends in the market.

In a Tough Year for Pharma, These 6 Stocks Are Shining

LINCOLN, Neb.--(BUSINESS WIRE)---- $ZTS #Lincoln--Zoetis: NEWS FACTS Today, Zoetis, the world leader in Animal Health, marked the official opening of its new monoclonal antibodies (mAbs) expansion with a ribbon cutting ceremony at its site in Lincoln, Neb. The ceremony was attended by local officials, including U.S. Senator Pete Ricketts, Lincoln Mayor Gaylor Baird and key company leaders including Zoetis CEO Kristin Peck, and President of Global Manufacturing and Supply, Nick Ashton. This new facility will enab.

Zoetis Welcomes Officials to Open New State-of-the-Art Facility in Lincoln

LINCOLN, Neb.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis, the world's leading animal health company, is pleased to invite members of the media to attend a ribbon-cutting event to mark the official opening of our new monoclonal antibodies (mAbs) expansion, which will enable the site to increase production of products that control osteoarthritis pain in dogs and cats – our largest growing area of need for pet care customers. The site will also be a home for future innovation and serve as a Veterinary Medicine R&am.

Media Advisory: Ribbon Cutting Ceremony for new Zoetis facility in Lincoln, NE, to expand manufacturing capabilities and bring more jobs to Lincoln

Zoetis Inc. (NYSE:ZTS ) Q22023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Steve Frank - Vice President of Investor Relations Kristin Peck - Chief Executive Officer Wetteny Joseph - Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Nathan Rich - Goldman Sachs Jon Block - Stifel David Westenberg - Piper Sandler Brandon Vazquez - William Blair Louise Chen - Cantor Operator Welcome to the Second Quarter 2023 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis.

Zoetis Inc. (ZTS) Q22023 Earnings Call Transcript

Zoetis (ZTS) reports better-than-expected second-quarter 2023 results, beating both earnings and revenue estimates, primarily driven by the sales of its key dermatology products.

Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates

Zoetis (ZTS) came out with quarterly earnings of $1.41 per share, beating the Zacks Consensus Estimate of $1.32 per share. This compares to earnings of $1.20 per share a year ago.

Zoetis (ZTS) Beats Q2 Earnings and Revenue Estimates

Zoetis reported better-than-expected second-quarter sales and earnings, but ZTS stock fell on the company's lighter revenue outlook.

Zoetis Stock Slides As Rough Sales Outlook Chips Away At Quarterly Beat

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #Fortune500--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the second quarter of 2023 and updated its guidance for full year 2023. The company reported revenue of $2.2 billion for the second quarter of 2023, an increase of 6% compared with the second quarter of 2022. On an operational1 basis, revenue for the second quarter of 2023 increased 9% compared with the second quarter of 2022, excluding the impact of foreign currency. Net income for the second qua.

Zoetis Announces Second Quarter 2023 Results

Allegion

Domino's Pizza

Goldman Sachs

MarketAxess Holdings

MSCI

Rollins

Charles Schwab

Sirius XM Holdings Inc

SPDR S&P 500 ETF Trust

SS&C Technologies Hlds

Skyworks Solutions

Tractor Supply

W. R. Berkley

The watchlist from July posted a gain of 5.36% last month, outperforming the SPDR S&P 500 Trust ETF and Vanguard's Dividend Appreciation ETF. The top 15 dividend growth stocks for August offer an average dividend yield of 1.58% and appear about 32% undervalued based on dividend yield theory. Since inception, September 2020, the watchlist is beating VIG by 5.24% and SPY by 4.53%.

My Top 15 High Growth Dividend Stocks For August 2023

When Zoetis Inc. NYSE: ZTS reports second-quarter financials next week, the market will be expecting its best revenue growth in a year and a 9% jump in profits. If history repeats, the results will be even better.

Rising Dividend Make Zoetis a Doggone Winner

Zoetis (ZTS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zoetis (ZTS) Moves 6.9% Higher: Will This Strength Last?

Costco

Lennar

Microchip Technology

M&T Bank

UnitedHealth Group

Visa

This monthly series of articles focuses on DGI stocks that are likely to provide a high rate of dividend growth rather than a high current yield. We use our proprietary models to rate quantitatively and qualitatively and select the top ten names from an initial list of nearly 400 dividend stocks. A balanced portfolio should have a mix of high-dividend growth stocks and high-yield dividend stocks, depending on the life stage. If you are in the accumulation phase and are several years away from retirement, high-growth dividend stocks would be more appropriate for long-term growth.

Our Top 10 Picks For Dividend Growth Stocks - July 2023

Zoetis Inc., a leading veterinary health company, is expected to continue delivering strong earnings growth due to its dominant market position and increasing demand for pet and livestock healthcare. Despite a low dividend yield of 0.9%, Zoetis' impressive net income growth and steady margin expansion make it an attractive investment for long-term gains.

Zoetis: My Dog Approves Of This Dividend Compounder

Zoetis and Mastercard don't offer high yields, but both aggressively raised their payouts in recent years. Both companies have modest payout ratios, suggesting more hikes could be on the way.

2 Dividend Stocks That Doubled Their Payouts in 5 Years

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #Fortune500--Zoetis Inc. (NYSE:ZTS) today announced the addition of Ester Banque as Executive Vice President and President, U.S. Operations, for the company, effective July 10, 2023. Ms. Banque is an accomplished global senior executive with over 30 years of experience in health sciences with top tier pharmaceutical companies. Ester will be a member of the Zoetis Executive team and report to Chief Executive Officer Kristin Peck. “We are excited to welcome Ester Banque to l.

Zoetis Announces Appointment of Ester Banque as President of U.S. Operations for World Leader in Animal Health

DÜSSELDORF, GERMANY / ACCESSWIRE / July 6, 2023 / Numaferm, a Germany-based biotech company, specialized in the production of pepteins, and Zoetis, the global leading animal health company, have signed a licensing agreement for the development and production of defined veterinary therapeutics. Financial details of the deal were not disclosed.

Numaferm and Zoetis Sign License Agreement to Collaborate on Developing and Producing Proteins and Peptides

The average of price targets set by Wall Street analysts indicates a potential upside of 27.9% in Zoetis (ZTS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Zoetis (ZTS) Could Rally 27.94%: Here's is How to Trade

Dollar General

Kroger

The watchlist from June posted a gain of 8.91% last month, outperforming the SPDR S&P 500 Trust ETF by 2.43% and Vanguard's Dividend Appreciation ETF by 2.41%. The top 15 dividend growth stocks for July offer an average dividend yield of 1.66% and appear about 34% undervalued based on dividend yield theory. Since inception, September 2020, the watchlist is beating VIG by 4.20% and SPY by 3.81%.

My Top 15 High Growth Dividend Stocks For July 2023

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, Aug. 8, 2023. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2023 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentatio.

Zoetis to Host Webcast and Conference Call on Second Quarter 2023 Financial Results

After reaching an important support level, Zoetis (ZTS) could be a good stock pick from a technical perspective. ZTS surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.

Zoetis (ZTS) Just Reclaimed the 20-Day Moving Average

Zoetis Inc. ( ZTS , Financial) is a leading animal health company with a diversified product portfolio of medicines and vaccines that aim to treat and protect livestock and companion animals.

There Are Plenty of Reasons to Like Zoetis

Zoetis, a global leader in the animal health industry, has beaten the S&P 500 over the last five years and offers diverse growth opportunities. The company has a strong international presence, a commitment to innovation, and a focus on key growth areas such as dermatology, parasiticides, pain, diagnostics, and emerging markets. Despite a high valuation and significant debt, Zoetis is a high-quality business that could reward patient, long-term investors.

News for Zoetis Stock (ZTS)